Moderna has wrapped phase III enrollment of its COVID-19 vaccine clinical trials. The company issued a statement regarding trial demographics, noting that high-risk groups make up 42% of the trial and 37% have a diverse background. With 21 strategically located global depots, Yourway can help facilitate trials worldwide.